Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | SQLE | Q14534 | 7/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2769830 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL20624673 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL932896 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL30531903 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL11892318 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL21260659 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL30531904 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL2495184 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| Hydrochloric Acid SCHEMBL8940577 | 0.98 | KMT2A (0.70) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL352058 | 0.98 | KMT2A (0.68) | KMT2ASQLEMAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0511205-B1 | PROCESS FOR PRODUCING 2-ETHYLHEXYL-P-METHOXYCINNAMATE | ISP VAN DYK INC (US) | 1995-01-25 | — | — | EP | claimed |
| JP-9291030-A | — | — | None | — | — | JP | disclosed |
| JP-10218764-A | — | — | None | — | — | JP | disclosed |
| JP-11130670-A | — | — | None | — | — | JP | disclosed |
| JP-7188119-A | — | — | None | — | — | JP | disclosed |
| WO-2020128981-A1 | DISCOVERY OF BD OXIDASE INHIBITORS FOR THE TREATMENT OF MYCOBACTERIAL DISEASES | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-2567956-A1 | NOVEL PRENYLARENE COMPOUND AND USE THEREOF | Osaka University (JP) | 2013-03-13 | — | — | EP | disclosed |
| JP-2011207802-A | BIRTH RATE INCREASE PROMOTER APPLIED TO MAMMALS, TRANQUILIZER APPLIED TO MAMMALS, AND FEED FOR LIVESTOCK | NAGASAKIKEN KORITSU DAIGAKU HOJIN | 2011-10-20 | — | — | JP | disclosed |
| US-20090208458-A1 | Transcriptional inhibitor for human k-ras gene | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2009-08-20 | — | — | US | disclosed |
| EP-0862575-B1 | NOVEL GERANYLGERANYL-DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND RELATED PHARMACEUTICAL COMPOSITIONS | BALDACCI LAB SPA (IT) | 2004-02-11 | — | — | EP | disclosed |
| JP-H10218764-A | PANCREATIC CANCER-TREATING AGENT | TORAY IND INC | 1998-08-18 | — | — | JP | disclosed |
| EP-0810201-A1 | PREVENTIVE/REMEDY FOR LIVER DISEASE | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-12-03 | — | — | EP | disclosed |
| JP-H09291030-A | ANTICANCER DRUG CONTAINING GERANYLGERANYLAMINE DERIVATIVE AS ACTIVE INGREDIENT | KURARAY CO LTD | 1997-11-11 | — | — | JP | disclosed |
| JP-H07188119-A | AMINE DERIVATIVE AND ITS PRODUCTION | TAKASAGO INTERNATL CORP | 1995-07-25 | — | — | JP | disclosed |
| US-4977170-A | Isoprenoidamine compounds which are useful antiulcer agents | SHIONOGI & CO., LTD. (JP) | 1990-12-11 | — | — | US | disclosed |
| US-4900749-A | Isoprenoidamine compounds useful as antiulcer agents | SHIONOGI & CO., LTD. (JP) | 1990-02-13 | — | — | US | disclosed |
| EP-0110397-B1 | POLYPRENYL COMPOUND AND DRUG CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 1989-06-14 | — | — | EP | disclosed |
| US-4762829-A | ANTICOAGULANTS | EISAI CO., LTD. (JP) | 1988-08-09 | — | — | US | disclosed |
| US-4742058-A | AMIDES, ANTICOAGULANTS | EISAI CO., LTD. (JP) | 1988-05-03 | — | — | US | disclosed |
| EP-0194901-A2 | Isoprenoidamine derivatives, compositions containing them, their preparation, and their use | SHIONOGI & CO., LTD. (JP) | 1986-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208458-A1 | Transcriptional inhibitor for human k-ras gene | MYCBP, UPF1, MYC | KMT2A 614/4885SQLE 3789/4885MAPT 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.